Expert Insights

Josep Tabernero, MD, reviews updated safety data from an analysis of the phase 3 BREAKWATER trial, evaluating encorafenib plus cetuximab plus chemotherapy for BRAFV600E metastatic colorectal cancer, as presented at the 2022 ESMO Congress.

Arvind Dasari, MD, discusses results from phase 3 FRESNO-2 trial which demonstrated a significant survival benefit with fruquintinib for patients with highly refractory metastatic colorectal cancer.

Joseph Chao, MD, reviews his presentation on new and upcoming targeted agents in gastric cancer from the Great Debates and Updates in Gastrointestinal Malignancies virtual meeting in September 2022.

Simon Crabb, PhD, MBBS, reviews results from a randomized, double-blind phase 2 trial of maintenance rucaparib following chemotherapy in DNA repair deficiency biomarker-positive patients with metastatic urothelial carcinoma.

Evan Yu, MD, reviews the results from a phase 3 trial examining pembrolizumab plus olaparib in patients with heavily pretreated castration-resistant prostate cancer, demonstrating no improvement in survival compared to abiraterone or...

Sharyn Katz, MD, MTR, provides an overview on the potential for diagnostic ambiguity in the radiology of Covid-19, a topic she presented at the 2022 GDU Lung Cancers virtual meeting.

Thomas Martin, MD, discusses an updated analysis of the CARTITUDE-1 trial, in which ciltacabtagene autoleucel maintained deep and durable responses in heavily pretreated patients with MM at a follow-up of 28 months.

Corey Langer, MD, provides an overview on the potential of immune checkpoint inhibitors for the treatment of malignant pleural mesothelioma, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.

Corey Langer, MD, provides an overview on the potential for immune checkpoint inhibitors in the treatment of thymic malignancies, a topic he presented at the 2022 GDU Lung Cancers virtual meeting.